First Time Loading...
T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 2 648.95 INR 0.7% Market Closed
Updated: May 16, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

104.7B
+2%
Revenue
Growth Rates:
1 Year
+13%
3 Years
+31%
5 Years
+39%
7 Years
+77%
10 Years
+174%
24.1B
+5%
Operating Income
Growth Rates:
1 Year
+21%
3 Years
+35%
5 Years
+90%
7 Years
+86%
10 Years
+228%
15B
+12%
Net Income
Growth Rates:
1 Year
+81%
3 Years
+21%
5 Years
+84%
7 Years
+49%
10 Years
+183%

Earnings Waterfall
Torrent Pharmaceuticals Ltd

Revenue
104.7B INR
Cost of Revenue
-27.1B INR
Gross Profit
77.6B INR
Operating Expenses
-53.5B INR
Operating Income
24.1B INR
Other Expenses
-9.1B INR
Net Income
15B INR

Income Statement
Torrent Pharmaceuticals Ltd

Rotate your device to view
Income Statement
Currency: INR
Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
38 285
N/A
41 847
+9%
43 267
+3%
45 717
+6%
47 247
+3%
46 535
-2%
54 865
+18%
59 625
+9%
63 365
+6%
66 869
+6%
62 889
-6%
60 249
-4%
59 259
-2%
58 569
-1%
56 679
-3%
56 559
0%
56 759
+0%
59 498
+5%
64 598
+9%
69 368
+7%
75 248
+8%
76 728
+2%
78 228
+2%
79 338
+1%
78 488
-1%
79 393
+1%
79 733
+0%
79 853
+0%
80 143
+0%
80 048
0%
80 828
+1%
82 028
+1%
83 158
+1%
85 080
+2%
87 210
+3%
88 750
+2%
92 580
+4%
96 202
+4%
98 642
+3%
102 332
+4%
104 742
+2%
Gross Profit
Cost of Revenue
(11 652)
(13 005)
(12 405)
(13 205)
(13 745)
(14 746)
(15 318)
(15 268)
(15 268)
(17 457)
(15 963)
(16 213)
(17 133)
(19 298)
(17 567)
(17 737)
(17 017)
(17 768)
(18 305)
(19 605)
(21 485)
(23 217)
(22 207)
(22 107)
(21 727)
(22 525)
(21 429)
(21 589)
(21 789)
(22 353)
(21 994)
(22 404)
(23 164)
(25 375)
(25 140)
(25 600)
(26 520)
(28 277)
(27 252)
(27 442)
(27 112)
Gross Profit
26 633
N/A
28 842
+8%
30 862
+7%
32 512
+5%
33 502
+3%
31 789
-5%
39 546
+24%
44 356
+12%
48 096
+8%
49 412
+3%
46 927
-5%
44 037
-6%
42 127
-4%
39 271
-7%
39 113
0%
38 823
-1%
39 743
+2%
41 730
+5%
46 294
+11%
49 764
+7%
53 764
+8%
53 511
0%
56 021
+5%
57 231
+2%
56 761
-1%
56 868
+0%
58 304
+3%
58 264
0%
58 354
+0%
57 695
-1%
58 834
+2%
59 624
+1%
59 994
+1%
59 706
0%
62 070
+4%
63 150
+2%
66 060
+5%
67 925
+3%
71 390
+5%
74 890
+5%
77 630
+4%
Operating Income
Operating Expenses
(19 274)
(19 314)
(20 847)
(21 897)
(22 967)
(23 494)
(25 942)
(26 342)
(26 352)
(24 458)
(26 832)
(27 912)
(29 162)
(28 433)
(29 929)
(29 799)
(30 499)
(32 324)
(35 787)
(38 497)
(41 097)
(39 824)
(41 827)
(42 467)
(42 277)
(41 679)
(41 954)
(40 994)
(40 454)
(39 411)
(40 435)
(41 005)
(42 065)
(42 012)
(43 929)
(44 769)
(46 079)
(46 524)
(49 605)
(52 025)
(53 515)
Selling, General & Administrative
(6 939)
(17 439)
(7 531)
(7 951)
(8 151)
(20 203)
(8 648)
(8 478)
(8 498)
(18 804)
(8 874)
(9 394)
(9 714)
(21 888)
(10 044)
(10 284)
(10 674)
(24 211)
(12 183)
(12 783)
(13 743)
(28 978)
(14 388)
(14 538)
(14 398)
(29 089)
(14 210)
(14 260)
(14 350)
(28 230)
(14 516)
(14 776)
(15 026)
(30 606)
(15 615)
(15 665)
(16 015)
(34 472)
(17 567)
(18 657)
(19 387)
Research & Development
0
(173)
0
0
0
(149)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(925)
0
0
0
(252)
0
0
0
(387)
0
0
0
(313)
0
0
0
Depreciation & Amortization
(859)
(870)
(870)
(1 210)
(1 540)
(1 907)
(2 267)
(2 297)
(2 347)
(2 376)
(2 486)
(2 586)
(2 726)
(2 934)
(3 189)
(3 339)
(3 549)
(4 086)
(4 786)
(5 466)
(6 086)
(6 144)
(6 277)
(6 387)
(6 457)
(6 515)
(6 554)
(6 574)
(6 614)
(6 573)
(6 618)
(6 648)
(6 648)
(6 619)
(6 522)
(6 472)
(6 732)
(7 020)
(7 426)
(7 806)
(8 006)
Other Operating Expenses
(11 477)
(832)
(12 446)
(12 736)
(13 276)
(1 235)
(15 026)
(15 566)
(15 506)
(3 278)
(15 473)
(15 933)
(16 723)
(3 610)
(16 696)
(16 176)
(16 276)
(4 026)
(18 819)
(20 249)
(21 269)
(4 702)
(21 163)
(21 543)
(21 423)
(5 150)
(21 190)
(20 160)
(19 490)
(4 357)
(19 301)
(19 581)
(20 391)
(4 400)
(21 793)
(22 633)
(23 333)
(4 719)
(24 612)
(25 562)
(26 122)
Operating Income
7 359
N/A
9 528
+29%
10 015
+5%
10 615
+6%
10 535
-1%
8 295
-21%
13 604
+64%
18 014
+32%
21 744
+21%
24 955
+15%
20 095
-19%
16 125
-20%
12 965
-20%
10 839
-16%
9 184
-15%
9 024
-2%
9 244
+2%
9 407
+2%
10 507
+12%
11 267
+7%
12 667
+12%
13 687
+8%
14 194
+4%
14 764
+4%
14 484
-2%
15 189
+5%
16 350
+8%
17 270
+6%
17 900
+4%
18 284
+2%
18 399
+1%
18 619
+1%
17 929
-4%
17 693
-1%
18 141
+3%
18 381
+1%
19 981
+9%
21 400
+7%
21 785
+2%
22 865
+5%
24 115
+5%
Pre-Tax Income
Interest Income Expense
(487)
(1 011)
(746)
(1 136)
(1 476)
1 158
(2 062)
(2 002)
(1 932)
(154)
(1 780)
(1 810)
(1 860)
193
(2 126)
(2 126)
(2 446)
(82)
(3 745)
(4 495)
(5 025)
(4 465)
(5 038)
(4 938)
(4 718)
(3 285)
(4 307)
(4 067)
(3 867)
(3 035)
(3 243)
(3 033)
(2 743)
(661)
(2 421)
(2 401)
(2 801)
(3 160)
(3 814)
(4 034)
(3 814)
Non-Reccuring Items
(375)
0
0
0
0
0
0
0
(1 940)
(1 936)
(1 936)
(1 936)
4
(135)
0
0
0
0
0
0
0
(3 603)
(3 570)
(3 570)
(3 570)
(29)
0
0
0
(5)
0
0
0
(4 849)
(4 847)
(4 847)
(4 847)
(46)
0
0
880
Gain/Loss on Disposition of Assets
0
(41)
0
0
0
11
0
0
0
34
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
216
0
0
0
Total Other Income
362
(36)
791
1 411
1 961
(66)
3 116
3 106
3 006
536
1 766
1 486
1 436
(16)
3 023
3 373
3 613
(15)
2 208
1 528
818
(2)
501
741
1 241
(10)
1 053
773
323
19
927
1 377
1 777
76
1 866
1 516
936
61
491
591
361
Pre-Tax Income
6 859
N/A
8 440
+23%
10 060
+19%
10 890
+8%
11 020
+1%
9 398
-15%
14 658
+56%
19 118
+30%
20 878
+9%
23 434
+12%
18 144
-23%
13 864
-24%
12 544
-10%
10 881
-13%
10 081
-7%
10 271
+2%
10 411
+1%
9 310
-11%
8 970
-4%
8 300
-7%
8 460
+2%
5 617
-34%
6 087
+8%
6 997
+15%
7 437
+6%
11 866
+60%
13 096
+10%
13 976
+7%
14 356
+3%
15 263
+6%
16 083
+5%
16 963
+5%
16 963
N/A
12 259
-28%
12 739
+4%
12 649
-1%
13 269
+5%
18 472
+39%
18 462
0%
19 422
+5%
21 542
+11%
Net Income
Tax Provision
(1 545)
(1 801)
(2 351)
(2 331)
(2 371)
(1 888)
(3 208)
(4 558)
(5 088)
(6 102)
(4 392)
(3 132)
(2 422)
(1 545)
(1 785)
(2 005)
(3 855)
(2 529)
(2 439)
(2 019)
(299)
(1 254)
(1 194)
(1 454)
(1 844)
(2 147)
(2 327)
(2 547)
(2 467)
(2 744)
(3 474)
(4 294)
(4 774)
(4 487)
(4 727)
(4 677)
(4 957)
(6 019)
(5 769)
(5 989)
(6 509)
Income from Continuing Operations
5 313
6 639
7 709
8 559
8 649
7 510
11 450
14 560
15 790
17 333
13 753
10 733
10 123
9 336
8 296
8 266
6 556
6 781
6 531
6 281
8 161
4 363
4 893
5 543
5 593
9 719
10 769
11 429
11 889
12 519
12 609
12 669
12 189
7 772
8 012
7 972
8 312
12 452
12 692
13 432
15 032
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Income (Common)
5 313
N/A
6 639
+25%
7 709
+16%
8 559
+11%
8 649
+1%
7 509
-13%
11 449
+52%
14 559
+27%
15 789
+8%
17 332
+10%
13 752
-21%
10 732
-22%
10 122
-6%
9 336
-8%
8 296
-11%
8 266
0%
6 556
-21%
6 781
+3%
6 531
-4%
6 281
-4%
8 161
+30%
4 363
-47%
4 893
+12%
5 543
+13%
5 593
+1%
10 247
+83%
11 297
+10%
11 957
+6%
12 417
+4%
12 519
+1%
12 609
+1%
12 669
+0%
12 189
-4%
7 772
-36%
8 012
+3%
7 972
0%
8 312
+4%
12 452
+50%
12 692
+2%
13 432
+6%
15 032
+12%
EPS (Diluted)
15.7
N/A
19.64
+25%
22.8
+16%
25.32
+11%
25.58
+1%
22.21
-13%
33.87
+52%
43.07
+27%
46.71
+8%
51.27
+10%
40.68
-21%
31.74
-22%
29.94
-6%
27.62
-8%
24.54
-11%
24.45
0%
19.39
-21%
20.06
+3%
19.37
-3%
18.52
-4%
24.13
+30%
12.89
-47%
14.46
+12%
16.44
+14%
16.56
+1%
30.31
+83%
33.42
+10%
35.37
+6%
36.62
+4%
37.03
+1%
37.3
+1%
37.37
+0%
36.05
-4%
22.99
-36%
23.63
+3%
23.57
0%
24.51
+4%
36.79
+50%
37.53
+2%
39.63
+6%
44.44
+12%

See Also

Summary
TORNTPHARM intrinsic value, competitors valuation, and company profile.
DCF Valuation
TORNTPHARM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TORNTPHARM stock valuation using valuation multiples.
Wall Street Estimates
TORNTPHARM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TORNTPHARM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.